許家印:恆大新能源汽車能實現2025年產銷百萬輛目標
恆大主席許家印表示,恆大新能源汽車一定能實現到2025年產銷100萬輛、2035年產銷500萬輛的宏偉目標。
許家印連續兩日到訪深圳恆大全球電池研究院,和上海恆大汽車全球研究總院,指恆大汽車研究總院克服了疫情帶來的重重困難和挑戰,在研發上取得了顯著進展,聽取介紹後感到非常振奮。
目前恆大汽車全球研究總院在全球擁有約3,200名科研人員,研究總院內下設前瞻技術研究院、整車技術研究院、軟體技術研究院、動力研究院、造型研究院、第一車型 研發院、第二車型研發院、第三車型研發院、全球電池研究院、日本研究院、 瑞典研發中心等11大專業研究院。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.